187 related articles for article (PubMed ID: 22842582)
1. Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Grell P; Fabian P; Khoylou M; Radova L; Slaby O; Hrstka R; Vyzula R; Hajduch M; Svoboda M
Int J Oncol; 2012 Oct; 41(4):1204-12. PubMed ID: 22842582
[TBL] [Abstract][Full Text] [Related]
2. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Gori S; Sidoni A; Colozza M; Ferri I; Mameli MG; Fenocchio D; Stocchi L; Foglietta J; Ludovini V; Minenza E; De Angelis V; Crinò L
Ann Oncol; 2009 Apr; 20(4):648-54. PubMed ID: 19188134
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Tural D; Serdengecti S; Demirelli F; Öztürk T; İlvan S; Turna H; Özgüroglu M; Büyükünal E
Br J Cancer; 2014 Apr; 110(8):1968-76. PubMed ID: 24595002
[TBL] [Abstract][Full Text] [Related]
4. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
Gallardo A; Lerma E; Escuin D; Tibau A; Muñoz J; Ojeda B; Barnadas A; Adrover E; Sánchez-Tejada L; Giner D; Ortiz-Martínez F; Peiró G
Br J Cancer; 2012 Apr; 106(8):1367-73. PubMed ID: 22454081
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Fabi A; Metro G; Di Benedetto A; Nisticò C; Vici P; Melucci E; Antoniani B; Perracchio L; Sperduti I; Milella M; Cognetti F; Mottolese M
Oncology; 2010; 78(2):141-9. PubMed ID: 20389136
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
7. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
Okutur K; Bassulu N; Dalar L; Aydin K; Bozkurt M; Pilanci KN; Dogusoy GB; Tecimer C; Mandel NM; Demir G
Asian Pac J Cancer Prev; 2015; 16(7):2645-51. PubMed ID: 25854340
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.
Yonemori K; Tsuta K; Shimizu C; Hatanaka Y; Hashizume K; Ono M; Kouno T; Ando M; Tamura K; Katsumata N; Hasegawa T; Kinoshita T; Fujiwara Y
Med Oncol; 2009; 26(3):344-9. PubMed ID: 19016009
[TBL] [Abstract][Full Text] [Related]
11. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
12. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
13. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
14. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
[TBL] [Abstract][Full Text] [Related]
15. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
16. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
17. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
18. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA
Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874
[TBL] [Abstract][Full Text] [Related]
19. Activation of PI3K/Akt signaling and hormone resistance in breast cancer.
Tokunaga E; Kimura Y; Mashino K; Oki E; Kataoka A; Ohno S; Morita M; Kakeji Y; Baba H; Maehara Y
Breast Cancer; 2006; 13(2):137-44. PubMed ID: 16755107
[TBL] [Abstract][Full Text] [Related]
20. p95-HER2 and trastuzumab resistance in metastatic breast cancer; is immunohistochemistry appropriate?
Kocar M; Bozkurtlar E; Telli F; Yumuk F; Kaya H; Kocar H; Serdar Turhal N
J BUON; 2014; 19(1):245-9. PubMed ID: 24659671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
